JANE CHUNG, R.Ph.
Chief Executive Officer & Member, Board of Directors
“Our unique technology and extensive discovery and development toolkit of antibodies, linkers, and payloads enable us to reimagine every aspect of ADC design in our mission to deliver transformative medicines and benefit to patients.”
Jane Chung, R.Ph., has served as the Chief Executive Officer and a member of the Board of Directors of Sutro since March 2025, drawing on more than 20 years of pharmaceutical and biotechnology leadership experience. Prior to her appointment as CEO, Jane served as Sutro’s President and Chief Operating Officer, and previously as Chief Commercial Officer.
Before joining Sutro, Jane held several leadership roles at AstraZeneca, including President and General Manager of AstraZeneca Canada, Vice President of Sales and Marketing of U.S. lmmuno-Oncology, and Senior Commercial Business Director. Earlier, she served as a Regional Sales Director and Director of Sales Productivity and Effectiveness for Onyx Pharmaceuticals Inc., and held several commercial roles of increasing responsibility at Genentech, Inc., including Commercial Operations Manager, Division Manager and Senior Marketing Manager.
In addition, Jane has also served on the Board of Directors of Viracta Therapeutics, Inc., as well as on several nonprofit boards across science, education, and community development. She holds a B.A. from Columbia University, New York, and B.S. in Pharmacy from St. John’s University, New York.